



SHORELINE
biosciences

Corporate Overview
Q3 2021

Shoreline Biosciences

Advancing the Next Generation of iPSC-derived NK and Macrophage Immunotherapies

Our Vision



To create safe, effective and affordable immunotherapies for the treatment of seriously ill patients.

Our Mission



Through innovative thinking, intelligent design and tenacity, we strive to discover and develop clinically effective iPSC-derived allogeneic immunotherapies to save lives.



Led by World Class Team, Supported by Prominent Investors

Executive Management

Chief Executive Officer,
Chairman



Kleanthis G.
Xanthopoulos, PhD



Chief Medical Officer,
Co-Founder



William Sandborn, MD



Chief Scientific Officer,
Co-Founder



Dan Kaufman, MD, PhD



Chief Financial Officer



Vanessa Jacoby, CPA



Chief Business Officer,
Co-Founder



Steven Holtzman



Senior Vice President,
Head of CMC



Mohammad
El-Kalay, PhD



SVP, Global Clinical
Development



Boyan Litchev, MD



VP, Alliance and
Project Management



Steve Neben, PhD



VP, Smart
Manufacturing




Bjorn Dahle, MBA



Shoreline Biosciences: Core Cell Therapy Technologies

Engineered iPSC-NK Cells




- ✓ Persistence
- ✓ Metabolic Fitness
- ✓ Polyfunctionality


Optimized CARs




Optimized for ADCC*



Universal Engagers



Engineered iPSC-Macrophages



- ✓ Improved Yield
- ✓ Transduction
- ✓ Penetrance

*ADCC:
Antibody Dependent Cellular Cytotoxicity

Shoreline Biosciences: Core Cell Therapy Technologies

Engineered
iPSC-NK Cells

Optimized
CARs


Optimized for ADCC

Universal Engagers


Engineered iPSC-
Macrophages

NK Cell Engine #1
CISH KO

- ✓ Persistence
- ✓ Metabolic Fitness
- ✓ Polyfunctionality
- Cell Exhaustion



+



NK Cell Engine #2
ADAM17 KO

- ✓ Stabilized CD16
- ✓ Cytotoxicity
- ✓ Tissue Horning

Advanced, precise and multi-gene editing technologies

Shoreline Biosciences: Core Cell Therapy Technologies

Engineered
iPSC-NK Cells

Optimized
CARs


Optimized for ADCC

Universal Engagers


Engineered iPSC-
Macrophages

scFv developed for
direct tumor
engagement

Signaling domains
rationally designed
and screened for
optimal cell activity



NK Cell Specific CARs



Macrophage Specific CARs

Shoreline Biosciences: Core Cell Therapy Technologies

Engineered
iPSC-NK Cells


Optimized
CARs

Optimized for ADCC

Universal Engagers

Engineered iPSC-
Macrophages

Super Affinity ADCC
Engager for mAbs



Shoreline Biosciences: Core Cell Therapy Technologies

Engineered
iPSC-NK Cells

Optimized
CARs

Optimized for ADCC

Universal Engagers

Engineered iPSC-
Macrophages


M1 Inflammatory



TAA #1 TAA #2 TAA #3



Universal scFv for
interaction with "switch"



Multi-antigen
tumor targeting

Shoreline Biosciences: Core Cell Therapy Technologies

Engineered
iPSC-NK Cells


Optimized
CARs

Optimized for ADCC*

Universal Engagers

Engineered iPSC-
Macrophages


M1 Inflammatory




- ✓ Improved Yield
- ✓ Transduction
- ✓ Penetrance

IL-1
IL-6
IFN gamma

Cell Targeting Using CAR and/or Antibody




M2 Resolving



IL-4
IL-10
TGF Beta

- ✓ Tissue Repair
- ✓ Hypoimmunity
- ✓ Persistence



Shoreline iPSC-NK Cells

Overview of Core Technologies

Shoreline's Next Gen iPSC-NK Cell Engine

Building off superior core NK cell product (CISH KO-NK) and implementing additional technologies for optimal activity against solid tumors

Hypersensitive to IL-15

↑ *CD122 Expression*



Reduced Cell Exhaustion

↓ *TIGIT Expression*



Polyfunctional Cytokine Response

Overcoming immunosuppressive TME in solid tumors

Extended *in vivo* Persistence

Infiltrating to solid tumors

Improved Metabolic Profile

